-
Synageva BioPharma Corp. was a
publicly listed biopharmaceutical company (Nasdaq: GEVA)
headquartered in Lexington, M****achusetts
dedicated to discovering...
- hypophosphatasia, for as much as $1.08 billion. In June 2015,
Alexion acquired Synageva, a
maker of rare
disease treatments, in an $8.4
billion stock-and-cash...
- into
Alexion Antibody Technologies Inc)
Enobia Pharma Corp (Acq 2011)
Synageva BioPharma (Acq 2015)
Wilson Therapeutics (Acq 2018)
Syntimmune (Acq 2018)...
- hypophosphatasia, a rare
metabolic disorder. In 2015
Alexion estimated that
Synageva, its
specialty drug for
lysosomal acid
lipase deficiency, a
fatal genetic...
- with
lysosomal acid
lipase (LAL) deficiency.
Sebelipase was
developed by
Synageva that
became part of
Alexion Pharmaceuticals in 2015. For its production...
-
Retrieved 1
November 2015.
Chelsey Dulaney (May 6, 2015). "Alexion to Buy
Synageva for $8.4 Billion". The Wall
Street Journal.
Retrieved May 7, 2015. "Valeant...
-
served as the
Chairman of the
Scientific Advisory Committees (SAC) of
Synageva BioPharma and
Kiniksa Pharmaceuticals. The
enzyme therapy developed in...
